Study to Assess Long-Term Outcomes of Trientine in Wilson Disease Patients Withdrawn From Therapy With d-Penicillamine
Multicentre, Retrospective and Prospective Study to Assess Long-Term Outcomes of Chelator-Based Treatment With Trientine in Wilson Disease Patients Withdrawn From Therapy With d-Penicillamine
Sponsor: Univar BV
A PHASE4 clinical study on Wilson Disease, this trial is ongoing. The trial is conducted by Univar BV and has accumulated 8 data snapshots since 2016. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE4
Status: Unknown Status → Unknown
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status PHASE4
-
Sep 2019 — Jan 2021 [monthly]
Unknown Status PHASE4
Status: Active Not Recruiting → Unknown Status
-
Jun 2018 — Sep 2019 [monthly]
Active Not Recruiting PHASE4
▶ Show 3 earlier versions
-
Sep 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE4
Status: Recruiting → Active Not Recruiting
-
Apr 2017 — Sep 2017 [monthly]
Recruiting PHASE4
-
Jan 2017 — Apr 2017 [monthly]
Recruiting PHASE4
First recorded
Jan 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Univar BV
For direct contact, visit the study record on ClinicalTrials.gov .